APGE — Apogee Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1974640 ·
Last close
$82.81
Market Cap
$5.13B
52W High
$95.32
52W Low
$65.22
ADV30
628,551
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -82,772,000 | -74,111,000 | 1,293,654,000 | 451,797,000 | 37,861,000 |
| Dec 2025 | 0 | — | -78,056,000 | -69,387,000 | 937,134,000 | 131,549,000 | 33,251,000 |
| Sep 2025 | 0 | — | -71,278,000 | -65,021,000 | 626,159,000 | 107,914,000 | 39,821,000 |
| Jun 2025 | 0 | — | -73,165,000 | -66,096,000 | 657,772,000 | 124,192,000 | 38,371,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-227,450,000
Investing CF
$-179,574,000
Financing CF
$396,490,000
CapEx
$-5,898,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.98
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-561,759,000
Inventory
—
Receivables
$5,961,000
ST Investments
$598,643,000
EBIT TTM
$-285,595,000
Pretax Income TTM
$-255,565,000
Interest Exp TTM
—
Analysts
16
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -285,595,000 | -255,843,000 | 937,134,000 | 33,251,000 | — | -227,450,000 |
| Dec 2024 | 0 | -216,870,000 | -182,146,000 | 753,951,000 | 37,157,000 | — | -171,174,000 |
| Dec 2023 | 0 | -93,003,000 | -83,985,000 | 401,404,000 | 21,491,000 | — | -74,761,000 |
| Dec 2022 | 0 | -30,727,000 | -39,785,000 | 152,055,000 | 9,980,000 | — | -16,427,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-5.27
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| CRSP | CRISPR Therapeutics AG | $4.98B | $51.59 | — |
| CGON | CG Oncology, Inc. | $5.46B | $61.89 | — |
| SRRK | Scholar Rock Holding Corp | $6.17B | $51.51 | — |
| RGEN | REPLIGEN CORP | $6.50B | $115.19 | — |
| TWST | Twist Bioscience Corp | $4.04B | $64.87 | — |
News headlines (Yahoo Finance, 1h cache)
Apogee Therapeutics to Host Conference Call to Report Part B 16-Week Data from the Phase 2 APEX Trial of Zumilokibart in Patients with Moderate-to-Severe Atopic Dermatitis on May 27, 2026
2026-05-26 20:01 · Yahoo
Apogee Therapeutics Provides Pipeline Progress and Reports First Quarter 2026 Financial Results
2026-05-11 11:00 · Yahoo
Apogee Therapeutics Inc. (APGE): Primary Challenger to Established Blockbusters
2026-04-27 14:05 · Yahoo
Apogee Therapeutics (APGE) Is Up 17.8% After $403 Million Follow-On Tied To Zumilokibart Data
2026-03-28 00:16 · Yahoo
Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $403 Million
2026-03-26 20:01 · Yahoo
Apogee CEO Sells 20,000 Shares as Stock Surges Nearly 100% in a Year, but Here's What Really Matters for Investors
2026-03-26 15:53 · Yahoo
Apogee Therapeutics, Inc. Announces Pricing of $350 Million Underwritten Public Offering
2026-03-25 01:53 · Yahoo
APGE Stock Up as Skin Disease Drug Shows Sustained 52-Week Efficacy
2026-03-24 14:26 · Yahoo
How Apogee, Up 20%, Plans To Take On Rival Regeneron's Eczema Drug
2026-03-23 20:06 · Yahoo
Apogee Therapeutics, Inc. Announces Proposed $300 Million Underwritten Public Offering
2026-03-23 20:01 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.